Analogs of ghrelin substituted at the N-terminal
AssigneeIpsen Pharma S.A.S.
InventorZheng Xin Dong
Life of this patent
Estimating the term…
Abstract
The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: (R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.
Claims27
A ghrelin analog compound according to formula (I):
- (R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 (I)
- wherein:
- A1 is Inp, 1-Apc or 4-Apc;
- A2 is Ser, Abu, Acc, Act, Aib, Ala, Ava, Thr or Val;
- A3 is Ser, Asp(NH—R3), Asp(O—R4), Cys(S—R5), Dab(S(O)2—R6), Dap(S(O)2—R7), Glu(NH—R8), Glu(O—R9), Ser(C(O)—R10), Thr(C(O)—R11) or HN—CH((CH2)n—N(R12R13))—C(O);
- A4 is Phe, Acc, Aic, Cha, 2-Fua, 1-Nal, 2-Nal, 2-Pal, 3-Pal, 4-Pal, hPhe, (X1,X2,X3,X4,X5)Phe, Taz, 2-Thi, 3-Thi, Trp or Tyr;
- A5 is Leu, Abu, Acc, Aib, Ala, Cha, Ile, hLeu, Nle, Nva, Phe, Tle or Val;
- A6 is Ser, Abu, Acc, Act, Aib, Ala, Gly, Thr or Val;
- A7 is Pro, Dhp, Dmt, 3-Hyp, 4-Hyp, Inc, Ktp, Oic, Pip, Thz or Tic;
- A8 is Glu, Acc, Aib, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn or HN—CH((CH2)n—N(R12R13))—C(O);
- A9 is His, Acc, Apc, Aib, 2-Fua, 2-Pal, 3-Pal, 4-Pal, (X1,X2,X3,X4,X5-)Phe, Taz, 2-Thi or 3-Thi;
- A10 is Gln, Acc, Aib, Asn, Asp or Glu;
- A11 is Arg, Apc, hArg, Dab, Dap, Lys, Orn or HN—CH((CH2)n—N(R12R13))—C(O);
- A12 is Val, Abu, Acc, Aib, Ala, Cha, Gly, Ile, Leu, Nle, Nva or Tle;
- A13 is Gln, Acc, Aib, Asn, Asp or Glu;
- A14 is Gln, Acc, Aib, Asn, Asp or Glu;
- A15 is Arg, Acc, Aib, Apc, hArg, Dab, Dap, Lys or Orn;
- A16 is Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn or deleted;
- A17 is Glu, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn, Asp(NH—R3), Asp(O—R4), Cys(S—R5), Dab(S(O)2—R6), Dap(S(O)2—R7), Glu(NH—R8), Glu(O—R9), Ser(C(O)—R10), Thr(C(O)—R11), HN—CH((CH2)n—N(R12R13))—C(O) or deleted;
- A18 is Ser, Abu, Acc, Act, Aib, Ala, Thr, Val or deleted;
- A19 is Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn or deleted;
- A20 is Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn or deleted;
- A21 is Pro, Dhp, Dmt, 3-Hyp, 4-Hyp, Inc, Ktp, Oic, Pip, Thz, Tic or deleted;
- A22 is Pro, Dhp, Dmt, 3-Hyp, 4-Hyp, Inc, Ktp, Oic, Pip, Thz, Tic or deleted;
- A23 is Ala, Abu, Acc, Act, Aib, Apc, Gly, Nva, Val or deleted;
- A24 is Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN—CH((CH2)n—N(R12R13))—C(O) or deleted;
- A25 is Leu, Abu, Acc, Aib, Ala, Cha, Ile, hLeu, Nle, Nva, Phe, Tle, Val or deleted;
- A26 is Gln, Aib, Asn, Asp, Glu or deleted;
- A27 is Pro, Dhp, Dmt, 3-Hyp, 4-Hyp, Inc, Ktp, Oic, Pip, Thz, Tic or deleted;
- A28 is Arg, Acc, Aib, Apc, hArg, Dab, Dap, Lys, Orn, HN—CH((CH2)n—N(R12R13))—C(O) or deleted;
- R1 is —OH, —NH2, —(C1-C30)alkoxy or NH—X6—CH2—Z0, wherein X6 is a (C1-C12)alkyl or (C2-C12)alkenyl and Z0 is —H, —OH, —CO2H or —C(O)—NH2;
- R2 is, H, (C1-C30)alkyl, (C1-C30)heteroallcyl, (C1-C30)acyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, aryl(C1-C30)acyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C2-C30)acyl, substituted (C2-C30)alkenyl, substituted aryl(C1-C30)alkyl, substituted (C2-C30)alkynyl or substituted aryl(C1-C30)acyl;
- each of R3, R4, R5, R6, R7, R8, R9, R10 and R11 is, independently for each occurrence thereof, selected from the group consisting of (C1-C40)alkyl, (C2-C40)alkenyl, substituted (C1-C40) alkyl, substituted (C2-C40) alkenyl, alkylaryl, substituted alkylaryl, aryl and substituted aryl;
- each of R12 and R13 is, independently for each occurrence thereof, selected from the group consisting of H, (C1-C40)alkyl, (C1-C40)heteroalkyl, (C1-C40)acyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, aryl(C1-C40)acyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroallcyl, substituted (C1-C40)acyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl, substituted aryl(C1-C40)alkyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl or —C(NH)—NH2;
- n is, independently for each occurrence thereof, 1, 2, 3, 4 or 5;
- each of X1, X2, X3, X4, and X5 is, independently for each occurrence thereof, selected from the group consisting of H, F, Cl, Br, I, (C1-10)alkyl, substituted (C1-10)alkyl, aryl, substituted aryl, OH, NH2, NO2 and CN;
- provided that:
- when R12 is (C1-C40)acyl, aryl(C1-C40)acyl, substituted (C1-C40)acyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl, or —C(NH)—NH2, then R13 is H or (C1-C40)alkyl, (C1-C40)heteroalkyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroalkyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl, or substituted aryl(C1-C40)alkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.